Perrigo to be first to file patent challenge for generic of Taro's Topicort 0.25%
Perrigo (NYSE: PRGO) has said it has filed an Abbreviated New Drug Application for desoximetasone topical spray 0.25%, currently marketed as Topicort by Taro (NYSE: TARO). Its annual sales were around $29 million, according to research by Symphony Health Solutions.
On Monday, Taro filed suit against Perrigo in the US District Court of Delaware, claiming patent infringement, formally initiating the process under the Hatch-Waxman Act. Perrigo believes it is the first filer for this opportunity, entitling it to 180 days of exclusivity as a generic.
Topicort is is a topical corticosteroid for the treatment of plaque psoriasis in adult patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze